glp-1 receptor agonists should be avoided in patients with Impact of GLP- 1 Agonist Therapy High Risk for Sarcopenia | Current Nutrition Reports GLP-1 Receptor Agonists for the

doi: 10.1038/nm.3009 44 CoskunTSloopKWLoghinCAlsina-FernandezJUrvaSBokvistKBet al

These effects were coupled to an amelioration in lipid metabolism and hepatic steatosis, which markedly exceeded the effect of single GLP-1RA treatment ( Oxyntomodulin, a gut-derived peptide hormone, activates both the GLP-1R and the GCGR, although, with reduced affinity compared to GLP-1 and glucagon, respectively

9 Helping plan members access effective treatments, including weight management medication, could help offset these costs and could boost employee recruitment and retention

Evolution of GLP-1-based therapeutics First-generation GLP-1RAs The development of GLP-1 receptor agonists stemmed from the significant finding that natural GLP-1 had an exceptionally short half-life of about 1.5 to 5 min, due to its rapid degradation by the enzyme DPP-4 (Campbell and Drucker 2013) (Fig